Maxigen Biotech Inc. reported consolidated revenue results for the month and year to date ended March 2022. On a consolidated basis, revenues were TWD 46.371 million, a decrease of 4.67% over the same period in 2021.

Revenues for January through March 2022 totaled TWD 123.262 million, an increase of 11.04% compared to the TWD 111.009 million for the same period in 2021.